CN104673760A - 一种原核细胞表达类病毒颗粒的纯化方法 - Google Patents
一种原核细胞表达类病毒颗粒的纯化方法 Download PDFInfo
- Publication number
- CN104673760A CN104673760A CN201310629523.8A CN201310629523A CN104673760A CN 104673760 A CN104673760 A CN 104673760A CN 201310629523 A CN201310629523 A CN 201310629523A CN 104673760 A CN104673760 A CN 104673760A
- Authority
- CN
- China
- Prior art keywords
- viruslike particle
- virus
- hepatitis
- purification process
- chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 68
- 210000001236 prokaryotic cell Anatomy 0.000 title claims description 6
- 238000000034 method Methods 0.000 title abstract description 16
- 241000726445 Viroids Species 0.000 title abstract 2
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 29
- 238000000746 purification Methods 0.000 claims abstract description 29
- 238000011210 chromatographic step Methods 0.000 claims abstract description 27
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960002897 heparin Drugs 0.000 claims abstract description 18
- 229920000669 heparin Polymers 0.000 claims abstract description 18
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 17
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 15
- 238000012870 ammonium sulfate precipitation Methods 0.000 claims abstract description 14
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 14
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 14
- 241000588724 Escherichia coli Species 0.000 claims abstract description 13
- 238000001556 precipitation Methods 0.000 claims abstract description 6
- 101710132601 Capsid protein Proteins 0.000 claims description 69
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 241000700721 Hepatitis B virus Species 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 16
- 238000004458 analytical method Methods 0.000 claims description 15
- 239000007853 buffer solution Substances 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 10
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 10
- 239000000945 filler Substances 0.000 claims description 10
- 239000001488 sodium phosphate Substances 0.000 claims description 10
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 10
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 10
- 241000737598 recombinant Hepatitis B virus Species 0.000 claims description 9
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 7
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 7
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- 239000001166 ammonium sulphate Substances 0.000 claims description 6
- -1 methacrylate ester Chemical class 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 229920002684 Sepharose Polymers 0.000 claims description 5
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000709715 Hepatovirus Species 0.000 claims description 2
- 241001631646 Papillomaviridae Species 0.000 claims description 2
- 241000702670 Rotavirus Species 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000012460 protein solution Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 2
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 101000936049 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) Outer membrane lipoprotein Blc Proteins 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BIGPRXCJEDHCLP-UHFFFAOYSA-N ammonium bisulfate Chemical compound [NH4+].OS([O-])(=O)=O BIGPRXCJEDHCLP-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000009567 fermentative growth Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
序列 | NCBI调取的总基因数 | HBcAg基因归类 |
1 | 1757 | China core |
2 | 23 | China adw2 |
3 | 123 | China adr |
4 | 3 | China ayr |
5 | 9 | China ayw |
6 | 1333 | genotype B China |
7 | 1249 | genotype C China |
8 | 280 | genotype A adw2 |
9 | 56 | genotype A adw |
10 | 71 | genotype A ayw |
11 | 279 | genotype B adw2 |
12 | 18 | genotype B ayw1 |
13 | 226 | genotype C adw2 |
14 | 553 | genotype C adr |
15 | 3 | genotype C ayr |
16 | 30 | Ba |
17 | 8 | Bj |
18 | 107 | C1 |
19 | 534 | C2 |
20 | 29 | C3 |
21 | 236 | adw2 |
22 | 55 | adw |
23 | 6 | ayr |
24 | 19 | ayw |
25 | 144 | adr |
26 | 1123 | genotype D |
27 | 521 | genotype E |
28 | 255 | genotype F |
29 | 18 | genotype G |
30 | 57 | genotype H |
Con183 | 9125 | consensus |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310629523.8A CN104673760B (zh) | 2013-11-29 | 2013-11-29 | 一种原核细胞表达类病毒颗粒的纯化方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310629523.8A CN104673760B (zh) | 2013-11-29 | 2013-11-29 | 一种原核细胞表达类病毒颗粒的纯化方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104673760A true CN104673760A (zh) | 2015-06-03 |
CN104673760B CN104673760B (zh) | 2018-01-02 |
Family
ID=53309354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310629523.8A Active CN104673760B (zh) | 2013-11-29 | 2013-11-29 | 一种原核细胞表达类病毒颗粒的纯化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104673760B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710527A (zh) * | 2015-02-28 | 2015-06-17 | 苏州金盟生物技术有限公司 | 一种生物制品的内毒素去除方法 |
CN108047316A (zh) * | 2018-01-04 | 2018-05-18 | 南京赛威信生物医药有限公司 | 重组乙肝核心抗原的分离纯化方法 |
WO2018119746A1 (zh) * | 2016-12-28 | 2018-07-05 | 北京民海生物科技有限公司 | 重组ev71病毒样颗粒的纯化及其疫苗制备方法 |
CN109517043A (zh) * | 2018-11-23 | 2019-03-26 | 艾美汉信疫苗(大连)有限公司 | 一种原核表达重组轮状病毒抗原p2-vp8的纯化方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995031532A1 (en) * | 1994-05-16 | 1995-11-23 | Merck & Co., Inc. | Papillomavirus vaccines |
CN1434056A (zh) * | 2002-01-25 | 2003-08-06 | 杭州泰士生物科技有限公司 | 一种重组人乙肝病毒核心抗原的生产方法 |
CN101153280A (zh) * | 2006-09-29 | 2008-04-02 | 厦门大学 | 从原核生物中纯化人乳头瘤病毒晚期蛋白l1的方法 |
CN102488899A (zh) * | 2011-12-15 | 2012-06-13 | 天津济命生生物科技有限公司 | 一种卵黄免疫球蛋白缓释制剂的制备方法和用途 |
CN103173470A (zh) * | 2013-03-11 | 2013-06-26 | 斯澳生物科技(苏州)有限公司 | 大肠杆菌来源的pcv2 orf2衣壳蛋白病毒样颗粒的制备 |
-
2013
- 2013-11-29 CN CN201310629523.8A patent/CN104673760B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995031532A1 (en) * | 1994-05-16 | 1995-11-23 | Merck & Co., Inc. | Papillomavirus vaccines |
CN1434056A (zh) * | 2002-01-25 | 2003-08-06 | 杭州泰士生物科技有限公司 | 一种重组人乙肝病毒核心抗原的生产方法 |
CN101153280A (zh) * | 2006-09-29 | 2008-04-02 | 厦门大学 | 从原核生物中纯化人乳头瘤病毒晚期蛋白l1的方法 |
CN102488899A (zh) * | 2011-12-15 | 2012-06-13 | 天津济命生生物科技有限公司 | 一种卵黄免疫球蛋白缓释制剂的制备方法和用途 |
CN103173470A (zh) * | 2013-03-11 | 2013-06-26 | 斯澳生物科技(苏州)有限公司 | 大肠杆菌来源的pcv2 orf2衣壳蛋白病毒样颗粒的制备 |
Non-Patent Citations (5)
Title |
---|
HENG CHEN等: "Expression and purification of the recombinant HBcAg core particles derived from methyltrophic Pichia pastoris, and TEM and AFM of the core particles and their natural aggregates", 《J ELECTRON MICROSC》 * |
刘广洋等: "乙型肝炎病毒核心抗原蛋白表达纯化及免疫学分析", 《药物生物技术》 * |
李记来等: "乙型肝炎病毒核心抗原的原核表达及纯化", 《中国生物制品学杂志》 * |
李静海等主编: "《展望21世纪的化学工程》", 31 August 2004 * |
郑裕国主编: "《生物工程设备》", 30 June 2007 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710527A (zh) * | 2015-02-28 | 2015-06-17 | 苏州金盟生物技术有限公司 | 一种生物制品的内毒素去除方法 |
CN104710527B (zh) * | 2015-02-28 | 2018-08-24 | 苏州金盟生物技术有限公司 | 一种生物制品的内毒素去除方法 |
WO2018119746A1 (zh) * | 2016-12-28 | 2018-07-05 | 北京民海生物科技有限公司 | 重组ev71病毒样颗粒的纯化及其疫苗制备方法 |
CN109689862A (zh) * | 2016-12-28 | 2019-04-26 | 北京民海生物科技有限公司 | 重组ev71病毒样颗粒的纯化及其疫苗制备方法 |
US10987416B2 (en) | 2016-12-28 | 2021-04-27 | Beijing Minhai Biotechnology Co., Ltd. | Purification of recombinant EV71 virus-like particle and method for preparing vaccine thereof |
CN109689862B (zh) * | 2016-12-28 | 2022-09-30 | 北京民海生物科技有限公司 | 重组ev71病毒样颗粒的纯化及其疫苗制备方法 |
CN108047316A (zh) * | 2018-01-04 | 2018-05-18 | 南京赛威信生物医药有限公司 | 重组乙肝核心抗原的分离纯化方法 |
CN109517043A (zh) * | 2018-11-23 | 2019-03-26 | 艾美汉信疫苗(大连)有限公司 | 一种原核表达重组轮状病毒抗原p2-vp8的纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104673760B (zh) | 2018-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108434450B (zh) | 基于铁蛋白纳米颗粒的疫苗及其制备方法 | |
CN109810976B (zh) | 猪塞内卡病毒全长感染性克隆的制备方法及应用 | |
GB2034323A (en) | Production of DNA Comprising B Hepatitis Viral Genome | |
CN104673760A (zh) | 一种原核细胞表达类病毒颗粒的纯化方法 | |
CN113564131B (zh) | 柯萨奇病毒a6型毒株及其应用 | |
CN1869215B (zh) | 一种制备人乳头瘤病毒的病毒样颗粒的方法 | |
CN104073473B (zh) | 一种pcv2病毒样颗粒及其制备方法和裂解及vlp组装缓冲液 | |
CN113564133B (zh) | 柯萨奇病毒a16型毒株及其免疫原性组合物和应用 | |
CN107043784A (zh) | 一种慢病毒载体的制备方法 | |
CN112175913A (zh) | SARS-CoV-2减毒株及其在预防新冠肺炎中的应用 | |
CN114774372A (zh) | 柯萨奇病毒a10型毒株及其疫苗和应用 | |
WO2021169768A1 (zh) | 一种口蹄疫病毒样颗粒体外组装的方法及其应用 | |
CN104531741B (zh) | 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用 | |
CN104513826A (zh) | 人乳头瘤病毒基因,及载体,菌株,表达方法 | |
CN102586287A (zh) | 一种hpv16l1多核苷酸序列及其表达载体、宿主细胞和应用 | |
CN110669142B (zh) | 融合rgd的猪圆环病毒2型病毒样颗粒、突变型感染性克隆及其制备方法和应用 | |
CN101857870A (zh) | Hpv58 l1基因及载体、菌株和表达方法 | |
CN113462655A (zh) | 检测新型冠状病毒的试剂和方法 | |
CN112430273A (zh) | 一种狂犬病毒表面的亚单位融合蛋白mG及其制备方法和应用 | |
CN104164374B (zh) | 用汉逊酵母表达系统产生hpv31 l1蛋白的方法 | |
CN104164447B (zh) | 用汉逊酵母表达系统产生hpv45 l1蛋白的方法 | |
RU2445357C1 (ru) | Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16 | |
CN102234661A (zh) | 人乳头瘤病毒类病毒颗粒的制备方法和外源蛋白表达盒、表达系统 | |
CN104120088B (zh) | 用汉逊酵母表达系统产生hpv58 l1蛋白的方法 | |
CN104120089B (zh) | 用汉逊酵母表达系统产生hpv52 l1蛋白的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU SAINUOWEI BIO-PHARM CO., LTD. Free format text: FORMER OWNER: JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. Effective date: 20150601 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150601 Address after: 210042 Nanjing Xuanwu Road, Jiangsu, No. 30 699-18 Applicant after: Jiangsu Sai Nuowei biological medicine company limited Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant before: Jiangsu Simcere Pharmaceutical Co., Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170405 Address after: 210042 Nanjing Xuanwu Road, Jiangsu, No. 30 699-18 Applicant after: Nanjing Weixin Biological Medicine Co., Ltd. Address before: 210042 Nanjing Xuanwu Road, Jiangsu, No. 30 699-18 Applicant before: Jiangsu Sai Nuowei biological medicine company limited |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 210 042 30 blocks, 699-18 Xuanwu Avenue, Nanjing, Jiangsu Province Patentee after: Nanjing Yuanda Saiweixin Biomedical Co., Ltd. Address before: 210 042 30 blocks, 699-18 Xuanwu Avenue, Nanjing, Jiangsu Province Patentee before: Nanjing Weixin Biological Medicine Co., Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 210031 preparation accelerator complex building, No.16 Pangu Road, Jiangbei new district, Nanjing City, Jiangsu Province Patentee after: Yuanda Weixin Life Science (Nanjing) Co.,Ltd. Address before: 210 042 30 blocks, 699-18 Xuanwu Avenue, Nanjing, Jiangsu Province Patentee before: Nanjing Yuanda Saiweixin Biomedical Co.,Ltd. |